ReviewReviewResearchers gathered many published studies and read them side by side, to see what keeps showing up.3 min read

MAPS Ibogaine Investigator's Brochure (July 2026): the most complete summary of ibogaine science

In short

In mid-2026 MAPS, a US nonprofit, gathered nearly everything science has published about ibogaine into one document for researchers and lawmakers. Why, if MAPS isn't studying it? So that more people will. It covers the Bwiti tradition; how ibogaine seems to act on many brain systems at once, without standing in for a drug the way methadone does; and what studies in addiction and PTSD have found. Ibogaine, it says, doesn't stand on its own: therapy and follow-up belong with it.

Card updated 10 October 2026: first publication

This page summarizes what formal research has documented. It is not everything known about iboga: the Bwiti tradition and decades of clinical experience are knowledge too. Before you read: what science sees, and what it can't.

Citation: Pluimer B (lead author); Harris R, Lucas P (editorial support). Ibogaine Investigator's Brochure (July 2026 IB), Version 1 (version date 1 June 2026; data cut-off 1 May 2026; effective 1 July 2026). San Jose, CA: Multidisciplinary Association for Psychedelic Studies (MAPS); 2026. 207 pp.
Read the original: MAPS ibogaine page
Access: Report · Free to read
At a glance: Literature compendium (investigator's brochure) · Covers studies in people, animals and cells · About 1,900 references

What it says

An investigator's brochure is the document researchers and regulators use to see everything known about a substance before a clinical trial. This one, from the Multidisciplinary Association for Psychedelic Studies, gathers ibogaine's pharmacology and how the body handles it, the toxicology from animal studies, every formal human study, the conditions that rule treatment out, and the steps it recommends to look after the heart. It also covers Gabon's 2026 heritage decree on iboga, and corrects several common claims about ibogaine's history and legal status. With roughly 1,900 references, it is the most complete single summary of the field available today.

Limits

MAPS presents the brochure as a literature compendium, not a clinical guide: it does not tell anyone how to treat a patient. It lists Mexico's legal status among the points it could not check against a primary government source. Some of its figures come second-hand from analyses not yet peer-reviewed. Its reuse licence is not stated, so we link to it and reproduce nothing from it.

How it fits

It is the backbone of our research hub and of our pages on how ibogaine works and on the heart. Where it leans on another review, such as the 2026 scoping review in Molecules, we cite that review too, and we treat the two as one line of evidence, not two.

Topics: Ibogaine research: what the science says
This summary is information, not medical advice. How we use sources

Reviewed by the IbogaQuest medical team · Last reviewed 10 October 2026

Was this summary helpful?